| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1934033 | Biochemical and Biophysical Research Communications | 2009 | 5 Pages |
Abstract
CD40L, the ligand for CD40 on dendritic cells (DCs), plays an important role in maturation and activation of DCs leading to induction of immune responses. Our previous studies showed that the mouse splenic CD4â8â DCs are tolerogenic and capable of stimulating suppressive type 1 CD4+ regulatory T (Tr1) cell responses via TGF-β secretion. In this study, we investigated whether CD40 ligation is able to convert tolerogenic CD4â8â DCs into immunogenic ones by in vitro treatment of DCs with anti-CD40 antibody. Our data showed that in vitro CD40 ligation with anti-CD40 antibody converted TGF-β-secreting tolerogenic CD4â8â DCs into IL-12-secreting immunogenic ones capable of stimulating type 1 CD4+ helper T (Th1) and CD8+ cytotoxic T lymphocyte (CTL) responses leading to induction of antitumor immunity. In addition, in vivo CD40 ligation by intratumoral injection of adenoviral vector AdVCD40L expressing CD40 ligand also induced tumor growth inhibition and regression of established P815 tumors with infiltration of tolerogenic CD4â8â DCs. Therefore, our data provide new information for and may thus have useful impacts in CD40 ligation-based immunotherapy of cancer.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Xueshu Zhang, Ross M. Kedl, Jim Xiang,
